SCHEMBL2477340

SCHEMBL2477340

CCOc1ccc(C)cc1OBOc1cc(C)ccc1OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
L3MBTL1 Q9Y468 8/20 0.53
RAB9A P51151 2/20 0.53
ATM Q13315 1/20 0.53
HPGD P15428 4/20 0.49
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 3/20 0.47
POLB P06746 3/20 0.45
ALDH1A1 P00352 3/20 0.45
ACHE P22303 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
NPSR1 Q6W5P4 4/20 0.41
MAPK1 P28482 2/20 0.41
USP2 O75604 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX12 P18054 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 3/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805356 0.86 MAPT (0.61) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL7634998 0.80 ACHE (0.68) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL4018504 0.79 L3MBTL1 (0.46) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL2477899 0.79 TSHR (0.49) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL188251 0.78 ACHE (0.71) MAPTL3MBTL1RAB9AHPGDTDP1
SCHEMBL16502112 0.77 MAPT (0.61) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL23271829 0.76 KDM4E (0.50) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL10190610 0.76 L3MBTL1 (0.50) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL7903433 0.76 ACHE (0.68) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL9886101 0.76 MAPT (0.60) MAPTL3MBTL1RAB9AATMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11664093-B2 Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-05-30 US disclosed
US-20200234798-A1 EXTRAPOLATIVE PREDICTION OF ENANTIOSELECTIVITY ENABLED BY COMPUTER-DRIVEN WORKFLOW, NEW MOLECULAR REPRESENTATIONS AND MACHINE LEARNING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2020-07-23 US disclosed
EP-2265583-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-12 EP disclosed
US-7723372-B2 Spiroindolinone derivatives HOFFMAN-LA ROCHE INC. (US) 2010-05-25 US disclosed
US-20090239889-A1 Spiroindolinone Derivatives LIU JIN-JUN 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239889-A1 Spiroindolinone Derivatives CCNY, RB1, NQO1 MAPT 4069/4885L3MBTL1 2230/4885RAB9A 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.